Program Co-leaders
The Tumor Immunology and Immunoengineeering (TII) Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is dedicated to understanding the immune regulation of malignant disease, and translating this knowledge into the development of novel diagnostic, preventive and treatment regimens. The program provides a forum to develop interdisciplinary strategies that promote innovative research, create new therapeutic options and reduce the burden of cancer.
The overall goal of the TII Program is to develop and implement immune-based strategies to prevent, treat, and/or monitor malignant diseases and disease progression. To achieve this goal, the program focuses on enhancing adaptive and innate antitumor responses and mitigating immunoinhibitory signals. The program includes both full and new members from University of Maryland Baltimore, University of Maryland College Park and University of Maryland Baltimore County.
Program Goal
To develop and implement immune-based strategies to treat and monitor cancer.
Program Aims
- AIM 1: Cancer and inflammation
Elucidate the roles for infection and inflammatory processes in cancer development. - AIM 2: Cell-based and regulatory pathway-targeted cancer immunotherapies
Employ novel approaches including immunoengineering techniques to enhance cell-based and regulatory pathway-targeted cancer immunotherapy strategies to reduce or modulate malignant cell growth. - AIM 3: Calibrating immune regulation
Develop strategies including immunoengineering approaches to overcome tumor-induced immunosuppression and to mitigate immunotherapy-related adverse effects.